| Generic Name |
Brand name |
Breast cancer stage |
Breast cancer subtype |
Type of therapy |
Where in the drug approval process is this treatment |
| Capecitabine |
Xeloda, and various generic versions |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Carboplatin |
Paraplatin |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Cisplatin |
Platinol, and various generic versions |
Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Cyclophosphamide |
Cytoxan, and various generic versions |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Docetaxel |
Taxotere, and various generic versions |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Doxorubicin |
Adriamycin, and various generic versions |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Epirubicin |
Pharmorubicin, and various generic versions |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Eribulin |
Halaven |
Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Fluorouracil Injection |
Fluorouracil Injection, and various generic versions |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Gemcitabine |
Gemzar, and various generic versions |
Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Lapatinib |
Tykerb |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Methotrexate |
Metoject |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Mitoxantrone |
Novantrone |
Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| nab-Paclitaxel |
Abraxane, and various generic versions |
Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Neratinib |
Nerlynx |
Stage I, Stage II, Stage III |
HR+, HER2+ |
Targeted therapy |
PCPA - Provincial & territorial price negotiation |
| Paclitaxel |
Taxol |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Pegylated Liposomal Doxorubicin |
Caelyx, and various generic versions |
Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |
| Pertuzumab |
Perjeta |
Stage I, Stage II, Stage III |
HER2+ |
Targeted therapy |
PCPA - Provincial & territorial price negotiation |
| Pertuzumab |
Perjeta |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Pertuzumab and Trastuzumab |
PHESGO |
Stage I, Stage II, Stage III |
HER2+ |
Targeted therapy |
CDA/INNESSS - Public funding review process |
| Pertuzumab and Trastuzumab |
PHESGO |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
PCPA - Provincial & territorial price negotiation |
| Trastuzumab |
Herceptin |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Herzuma |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Ontruzant |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Kanjinti |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Ogivri |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab biosimilar |
Trazimera |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab deruxtecan |
Enhertu |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab emtansine |
Kadcyla |
Stage I, Stage II, Stage III |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab emtansine |
Kadcyla |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Trastuzumab Subcutaneous |
Herceptin SC |
Stage I, Stage II, Stage III, Stage IV (metastatic) |
HER2+ |
Targeted therapy |
PCPA - Provincial & territorial price negotiation |
| Tucatinib |
Tukysa |
Stage IV (metastatic) |
HER2+ |
Targeted therapy |
Listed on Provincial/Territorial drug Formulary |
| Vinorelbine |
Navelbine, and various generic versions |
Stage IV (metastatic) |
HR+, HER2+, Triple Negative |
Chemotherapy |
Listed on Provincial/Territorial drug Formulary |